Aarti Drugs Limited Asset Resilience Ratio
Aarti Drugs Limited asset resilience ratio. Aarti Drugs Limited (AARTIDRUGS) has an Asset Resilience Ratio of 0.55% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Aarti Drugs Limited fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Aarti Drugs Limited (2006–2026)
Asset resilience ratio of Aarti Drugs Limited from 2006 to 2026. This chart shows how Aarti Drugs Limited's Asset Resilience Ratio has changed over time. Read total liabilities of Aarti Drugs Limited for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Aarti Drugs Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Aarti Drugs Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs154.70 Million | 0.55% |
| Total Liquid Assets | Rs154.70 Million | 0.55% |
Asset Resilience Insights
- Limited Liquidity: Aarti Drugs Limited maintains only 0.55% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Aarti Drugs Limited Industry Peers by Asset Resilience Ratio
Compare Aarti Drugs Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Aarti Drugs Limited Asset Resilience Ratio by Year (2006–2026)
Aarti Drugs Limited asset resilience ratio by year from 2006 to 2026. The table below shows the annual Asset Resilience Ratio data for Aarti Drugs Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 0.55% | Rs154.70 Million ≈ $1.67 Million |
Rs28.15 Billion ≈ $304.46 Million |
-0.04pp |
| 2025-03-31 | 0.58% | Rs150.50 Million ≈ $1.63 Million |
Rs25.75 Billion ≈ $278.44 Million |
+0.49pp |
| 2024-03-31 | 0.09% | Rs21.86 Million ≈ $236.39K |
Rs24.32 Billion ≈ $263.05 Million |
-0.41pp |
| 2023-03-31 | 0.50% | Rs122.10 Million ≈ $1.32 Million |
Rs24.21 Billion ≈ $261.87 Million |
-0.07pp |
| 2022-03-31 | 0.57% | Rs126.40 Million ≈ $1.37 Million |
Rs22.08 Billion ≈ $238.78 Million |
-0.12pp |
| 2021-03-31 | 0.69% | Rs122.05 Million ≈ $1.32 Million |
Rs17.66 Billion ≈ $190.99 Million |
-0.03pp |
| 2020-03-31 | 0.72% | Rs114.23 Million ≈ $1.24 Million |
Rs15.77 Billion ≈ $170.49 Million |
+0.11pp |
| 2019-03-31 | 0.61% | Rs89.22 Million ≈ $964.93K |
Rs14.63 Billion ≈ $158.20 Million |
-0.05pp |
| 2018-03-31 | 0.66% | Rs91.26 Million ≈ $986.96K |
Rs13.88 Billion ≈ $150.10 Million |
-0.02pp |
| 2017-03-31 | 0.68% | Rs80.27 Million ≈ $868.09K |
Rs11.77 Billion ≈ $127.33 Million |
-0.03pp |
| 2016-03-31 | 0.71% | Rs78.68 Million ≈ $850.92K |
Rs11.02 Billion ≈ $119.20 Million |
+0.15pp |
| 2015-03-31 | 0.57% | Rs56.95 Million ≈ $615.90K |
Rs10.02 Billion ≈ $108.36 Million |
+0.10pp |
| 2014-03-31 | 0.47% | Rs39.93 Million ≈ $431.87K |
Rs8.50 Billion ≈ $91.90 Million |
-0.04pp |
| 2013-03-31 | 0.51% | Rs36.35 Million ≈ $393.09K |
Rs7.20 Billion ≈ $77.83 Million |
-0.95pp |
| 2006-03-31 | 1.45% | Rs53.30 Million ≈ $576.45K |
Rs3.67 Billion ≈ $39.74 Million |
-- |
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more